Mayzent
siponimod · Novartis Europharm Limited
AUTHORISED IN THE EUWhat Mayzent is used for
Mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Mayzent
- Active substance
- siponimod
- Disease area
- Multiple Sclerosis, Relapsing-Remitting
- Medicine group
- Selective immunosuppressants
- ATC code
- L04
- Marketing authorisation holder
- Novartis Europharm Limited
- Authorised in the EU since
- 2020
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Mayzent used for?
Mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.
What is the active substance in Mayzent?
Mayzent contains siponimod.
Who makes Mayzent?
The EU marketing authorisation holder is Novartis Europharm Limited.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU